pre-IPO PHARMA

COMPANY OVERVIEW

AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. To do this, we first work to understand the areas of unmet need and the experience of living with any disease we are targeting. We then use our extensive experience in drug development to identify and advance therapies that can significantly improve clinical outcomes while offering the strongest opportunities for approval.


LOCATION

  • London, , UK
  • Durham, NC, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders
  • Rare Diseases

  • WEBSITE

    http://www.amo-pharma.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    woodford-investment-management


    PRESS RELEASES


    May 10, 2022

    AMO Pharma Announces Additional Private Equity Investment Following Progress in Phase 3 Study in Congenital Myotonic Dystrophy


    Dec 22, 2021

    AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy


    Oct 14, 2021

    Julia Jones Joins AMO Pharma As Chief Financial Officer And Board Member


    Sep 30, 2021

    AMO Pharma Announces First Patient Enrolled In REACH-CDM X 12-Month Open-Label Study


    Aug 19, 2021

    Accomplished Industry Executive Alan L. Rubino Named Chairman of AMO Pharma Board of Directors


    For More Press Releases


    Google Analytics Alternative